Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the ...

Modifi Biosciences, Inc., has announced that the company has been acquired by Merck, known as MSD outside of the United ...

Merck (MRK) and Moderna (MRNA) announced the initiation of INTerpath-009, a pivotal Phase 3 randomized clinical trial evaluating V940, an ...

Merck, a leading science and technology company, today announced a € 70 million expansion of its ADC manufacturing ...

Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange ...

In this article, we take a look at eight biotechs that have acquired funding in recent years to fortify their GPCR-focused ...

Summit Therapeutics may have a powerful new cancer therapy on its hands. Merck is milking its cash cow oncology drug ... In ...

Rahway: Merck, known as MSD outside of the United States and Canada, and Moderna, Inc., announced the initiation of INTerpath ...

The partners are also studying their personalized vaccine with Keytruda as an adjuvant NSCLC treatment for those who haven't gotten neoadjuvant therapy.

Graybosch covers the Healthcare sector, focusing on stocks such as Merck & Company, Arcus Biosciences ... It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across ...

This trial will assess an individualized neoantigen therapy plus Keytruda in some patients with non-small cell lung cancer.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...